×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
How Will the Increasing use of Real-World Evidence for Regulatory Decision-Making Impact QA Strategies and GCP Inspections?
Session Chair(s)
Andrew Gray, PhD
Director, QA Clinical Therapeutic Area Head
Johnson & Johnson, United Kingdom
This session will bring regulators and industry quality experts together to explore how quality management systems can be developed to meet the challenges real-world evidence presents to QA activities and regulatory inspection expectations.
Learning Objective : Evaluate quality challenges associated with the use of real-world evidence as part of regulatory studies; Discuss how to apply proportionate risk-based quality assurance activities which meet regulatory expectations.
Speaker(s)
FDA Update
L'Oreal Walker
FDA, United States
Supervisory Consumer Safety, OBIMO, ORA
FDA Update
Lee Pai-Scherf, MD
FDA, United States
Senior Physician, OSI, OC, CDER
Industry Perspective
Abi Seifert, MBA
Novartis , United States
Global Head Country Development Quality
Have an account?